Faeth Therapeutics, Inc. (FTH)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Josiah Craver CPA
|
Senior VP of Finance, Principal Financial Officer & Principal Accounting Officer | 391.15k | -- | -- |
|
Mr. Christopher W. Gerry J.D.
|
General Counsel & Secretary | 416.04k | -- | 1980 |
|
Mr. Anand Parikh Esq., J.D.
|
CEO, President & Chair | -- | -- | 1986 |
|
Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D.
|
Scientific Co-Founder | -- | -- | 1971 |
|
Dr. Lewis clayton Cantley Ph.D.
|
Scientific Co-Founder | -- | -- | 1949 |
|
Dr. Scott W. Lowe Ph.D.
|
Scientific Co-Founder | -- | -- | -- |
|
Dr. Gregory J. Hannon Ph.D.
|
Scientific Co-Founder | -- | -- | -- |
|
Dr. Karen H. Vousden Ph.D.
|
Scientific Co-Founder & Director | -- | -- | 1958 |
|
Mr. Oliver Maddocks Ph.D.
|
Co-Founder & Chief Scientific Officer | -- | -- | -- |
|
Dr. Benjamin Hopkins Ph.D.
|
Scientific Co-Founder | -- | -- | -- |
Faeth Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 29
Description
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Sensei Biotherapeutics, Inc. and changed its name to Faeth Therapeutics, Inc. in June 2026. The company was incorporated in 1999 and is headquartered in Rockville, Maryland.
Corporate Governance
Upcoming Events
November 3, 2026 at 1:30 PM UTC
Faeth Therapeutics, Inc. Earnings Date
